Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TARG10
- Development stage
- Preclinical
- Lead developer
- Targinta
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
TARG10 is a humanized monoclonal antibody (biologic) developed by Targinta AB, a subsidiary of Xintela AB. It specifically targets the cell surface receptor integrin α10β1, a tumor-associated antigen that is overexpressed in aggressive malignancies such as triple-negative breast cancer (TNBC) and glioblastoma, while maintaining low expression in normal tissues. By binding to and blocking the function of integrin α10β1, TARG10 inhibits the ability of cancer cells to grow, proliferate, migrate, and metastasize. The drug is currently in preclinical development, with manufacturing and cell line development supported by Abzena.
02
Targets
α10β1 (Integrin alpha 10 beta 1)
Beyond the preview
Go deeper on TARG10.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TARG10.